According to in vivo experiments performed on mice, platelet membrane-coated polymeric nanoparticles loaded with the anti-MM agent bortezomib and tissue plasminogen activator were able to selectively target MM in the bone marrow [95]. This evidence concerns the gene PLAT and Miyoshi myopathy.